A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) in Patients With Advanced Solid Tumors

Trial Profile

A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2018

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Bladder cancer; Breast cancer; Lung cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Biocad
  • Most Recent Events

    • 29 Aug 2018 Status changed from recruiting to active, no longer recruiting.
    • 29 Aug 2018 Planned End Date changed from 1 Sep 2017 to 1 Nov 2018.
    • 09 Mar 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top